June 10, 2019
WELLESLEY, Mass., June 10, 2019–The rising prevalence of cancer and infectious diseases are just two factors expected to shape the future of the exosome diagnostics and therapeutics market, according to a report by BCC Research, “Exosome Diagnostics and Therapeutics: Global Markets.”
The market expects to see a compound annual growth rate (CAGR) of 39.9% through 2023, when it could be worth $186.2 million.
“Research shows that all fluids in the human body contain exosomes, which can transfer cytoplasmic ingredients to other cells either locally or at distant sites,” notes report author Sathya Durga. “Once they reach the recipient cells, cytoplasmic ingredients can alter their biology. Thus, exosomes are widely being adopted by several end users, including hospitals, diagnostics centers and research institutions.”
Potential Seen for Stem Cell Technologies
Research has shown that mesenchymal stem cells have the ability to reverse acute and chronic kidney injury in different experimental models by paracrine/extracellular mechanisms, the report adds. The exchange of information between the injured cells and stem cells has the potential to be bidirectional, and the vesicles may either transfer transcripts from injured cells to stem cells, or it could go in the opposite direction. Overall, the paracrine hypothesis of MSC action has altered the outlook of the beneficial use of MSCs in regenerative medicine.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at email@example.com.
Exosome Diagnostics and Therapeutics: Global Markets( BIO149C )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.